BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 11134191)

  • 1. Tumor variants by hormone receptor expression in white patients with node-negative breast cancer from the surveillance, epidemiology, and end results database.
    Anderson WF; Chu KC; Chatterjee N; Brawley O; Brinton LA
    J Clin Oncol; 2001 Jan; 19(1):18-27. PubMed ID: 11134191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and prognosis of estrogen receptor-positive/progesterone receptor-negative male breast cancer: a population-based study.
    Wei JL; Zhang JX; Fu DY
    World J Surg Oncol; 2018 Dec; 16(1):236. PubMed ID: 30558615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
    Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
    Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups.
    Chu KC; Anderson WF; Fritz A; Ries LA; Brawley OW
    Cancer; 2001 Jul; 92(1):37-45. PubMed ID: 11443607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
    Zheng YZ; Wang L; Hu X; Shao ZM
    Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.
    Schinkel JK; Zahm SH; Jatoi I; McGlynn KA; Gallagher C; Schairer C; Shriver CD; Zhu K
    Cancer Causes Control; 2014 Aug; 25(8):959-68. PubMed ID: 24839049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.
    Brown M; Bauer K; Pare M
    Breast Cancer Res Treat; 2010 Feb; 120(1):217-27. PubMed ID: 19629680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population.
    Reiner AS; Lynch CF; Sisti JS; John EM; Brooks JD; Bernstein L; Knight JA; Hsu L; Concannon P; Mellemkjær L; Tischkowitz M; Haile RW; Shen R; Malone KE; Woods M; Liang X; Morrow M; Bernstein JL;
    Breast Cancer Res; 2017 Jul; 19(1):83. PubMed ID: 28724391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T3N0 invasive breast cancer? A SEER database analysis: outcomes by receptor status/race/age: analysis using the NCI Surveillance, Epidemiology, and End Results (SEER) database.
    Yan W; Christos P; Nori D; Chao KS; Ravi A
    Am J Clin Oncol; 2013 Dec; 36(6):552-7. PubMed ID: 22868241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The importance of temporal effects in evaluating the prognostic impact of joint ERPR expression in premenopausal women with node-positive breast cancer.
    Ouyang Y; Li D; Pater JL; Levine M
    Breast Cancer Res Treat; 2005 Jul; 92(2):115-23. PubMed ID: 15986120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Vergote I; Christiaens MR
    J Clin Pathol; 2005 Jun; 58(6):611-6. PubMed ID: 15917412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features and Survival of Single Hormone Receptor-Positive Breast Cancer: A Population-Based Study of 531,605 Patients.
    Lv M; Mao Y; Song Y; Wang Y; Liu X; Wang X; Nie G; Wang H
    Clin Breast Cancer; 2020 Oct; 20(5):e589-e599. PubMed ID: 32565109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of metastatic estrogen receptor and progesterone receptor status on survival.
    Lower EE; Glass EL; Bradley DA; Blau R; Heffelfinger S
    Breast Cancer Res Treat; 2005 Mar; 90(1):65-70. PubMed ID: 15770528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis.
    Liu J; Jiang W; Mao K; An Y; Su F; Kim BY; Liu Q; Jacobs LK
    Breast Cancer Res Treat; 2015 Apr; 150(2):439-45. PubMed ID: 25764167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A; Adli M; Eryigit Alkis H; Caglayan D
    J BUON; 2013; 18(3):619-22. PubMed ID: 24065473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.